News & Events
May 6, 2020
What You Need to Know About the Rare Disease Cures Accelerator-Data and Analytics PlatformJoin C-Path, the National Organization for Rare Disorders and the FDA for a free 1-hour webinar on the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), an integrated database and analytics hub designed to be used in building novel tools to accelerate drug development across rare diseases. Wednesday, May 6 at 1 PM EDT. Register......
April 30, 2020
C-Path Appoints Two New Members to Board of Directors
TUCSON, Ariz., April 30, 2020 — Tucson-based Critical Path Institute (C-Path) today announced the appointment of two new members to its Board of Directors: James W. Newman, CPA, former Executive Chairman of Victory Pharma, Inc. and Tomas Salmonson, Ph.D., M.Sc., former Chair of the Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMA).
April 29, 2020
C-Path ePRO Consortium and PRO Consortium Announce COVID-19 Risk Assessment and Mitigation Strategies
In collaboration with Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium, the Electronic Patient-Reported Outcome (ePRO) Consortium announces “Coronavirus Disease 2019 (COVID-19): Risk Assessment and Mitigation Strategies for the Collection of Patient-Reported Outcome Data through Clinical Sites.” The presentation focuses on the current challenges of capturing PRO data originally intended to be collected electronically (i.e., ePRO) from study participants during in-person visits to clinical trial sites. Recommended risk assessment and mitigation strategies are provided for consideration by trial sponsors and electronic clinical outcome assessment (eCOA) providers to facilitate the continued collection of PRO data in clinical trials.
April 29, 2020 - May 6, 2020
CANCELLED: 2020 Pediatric Academic Societies Meeting – International Stakeholder Collaboration to Develop Neonatal Therapeutics: How to Play Well in the Global Sandbox
C-Path’s International Neonatal Consortium (INC) will host a panel discussion at the 2020 Pediatric Academic Societies Meeting in Philadelphia, Saturday, May 2, titled, “International Stakeholder Collaboration to Develop Neonatal Therapeutics: How to Play Well in the Global Sandbox.” INC convenes academic experts, regulators, nurses, industry sponsor and patient/parent advocates from across the globe to forge a predictable regulatory path for evaluating the safety and effectiveness of therapies for neonates. More information…
April 28, 2020
C-Path Receives Letter of Support from EMA on Type 1 Diabetes Biomarker Initiative
The Critical Path Institute (C-Path) today announced that its Type 1 Diabetes (T1D) Consortium has received a letter of support from the European Medicines Agency (EMA) to facilitate the development and validation of the proposed regulatory qualification of pancreatic islet autoantibodies commonly used in clinical practice to diagnose T1D: insulin autoantibodies, glutamic acid decarboxylase 65, and insulinoma antigen-2 autoantibodies as enrichment biomarkers for T1D clinical trials.